Digbi Health, a genetics and gut-microbiome based digital care program for managing obesity and associated inflammatory digestive, skin, and cardiometabolic illnesses, completed a $5.4 million in Series A funding round.
Accel led the funding round with participation from Wisdom LLP, Ocean Azul Partners, and Seraph Venture.
The investment brings the company’s total funding to $8.5 million since its founding in 2018. The company plans to use the new funds to forge additional payer, employer, and third-party administrator partnerships and expand its product offering, engineering, gut microbiome, and data science teams in the US and India.
For insurance payers, ACOs, Digbi Health offers a value-based personalized population health platform for obesity and polychronic inflammatory illnesses – digestive, skin, and chronic pain. For employers, Digbi Health provides a personalized digital care platform for a diverse workforce, whose disease risk varies significantly by gender and ethnicity because they are rooted in the person’s genetic and gut microbiome.
“We are just starting to demonstrate the superior therapeutic power of combining gut-microbiome, genetics with lifestyle and clinical risk markers to recommend personalized, convenient, tiny changes in food and lifestyle that has remarkable impact on living a disease-free and full life,” said Digbi Health’s Founder and CEO, Ranjan Sinha.
“For the first time, people who suffer from two or more chronic illnesses do not have to struggle under the yoke of one-size-fits-all diet or deal with multiple care programs to deal with obesity and inflammatory illnesses. We use powerful science to get to the root cause of the illness and cure it from the inside out versus just masking or managing it like other programs,” added Sinha.
“Having the financial support of Accel will enable us to execute our vision even more rapidly and broadly – with consumers, payers, doctors, and employers.”
Digital Health companies raised $14.8 billion in 2020, a 66% increase compared to $8.9 billion in 2019. Recently, Vivante Health, a digital medicine provider for gut health and disease, closed its $5.8 million Series A1 funding round.